Preface by Luqmani, R, Jayne, D

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem). by Luqmani, R, Jayne, D

Ongoing european research initiatives in systemic vasculitides: The EUVAS program by Luqmani, R, Jayne, D

Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. by Luqmani, R, Jayne, D, Gaskin, G, EUVAS

Assessment of damage in vasculitis: expert ratings of damage. by Seo, P, Jayne, D, Luqmani, R, Merkel, P

Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes by Robson, J, Jayne, D, Merkel, P, Dawson, J

Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials by Luqmani, R, Bacon, P, Rasmussen, N, Jayne, D

Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials. by Luqmani, R, Bacon, P, Rasmussen, N, Jayne, D

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV) by Salisbury, E, McLaren, J, Jayne, D, Luqmani, R

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV) by Salisbury, E, McLaren, J, Jayne, D, Luqmani, R

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) by Salisbury, E, McLaren, J, Jayne, D, Luqmani, R

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. by Mukhtyar, C, Hellmich, B, Jayne, D, Flossmann, O, Luqmani, R

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv) by Salisbury, E, McLaren, J, Pathare, S, Jayne, D, Luqmani, R

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis by Luqmani, R, Flossmann, O, Jayne, D, Hellmich, B, Taskforce, E

Long-term follow up of EUVAS studies by Flossmann, O, Harper, L, Jayne, D, Luqmani, R, Westman, K

Fixed-interval repeat dose rituximab improves abnormalities in the periperhal B cell compartment and reduces relapse rates in ANCA associated vasculitis by Wallin, E, Smith, R, Jones, R, Jayne, D, Smith, K

Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis by Luqmani, R, Mukhtyar, C, Flossmann, O, Hellmich, B, Jayne, D

BIMODAL MORTALITY RISK IN WEGENER'S GRANULOMATOSIS by Luqmani, R, Edwards, C, Culliford, D, Maskell, J, Jayne, D, Arden, N

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV) by Mukhtyar, C, Flomann, O, Brown, D, Westman, K, Jayne, D, Luqmani, R

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. by Mukhtyar, C, Boumpas, D, Gordon, C, Gross, W, Jayne, D, Luqmani, R